Compare BETR & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BETR | TLSI |
|---|---|---|
| Founded | 2014 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 334.8M | 270.2M |
| IPO Year | 2021 | 2020 |
| Metric | BETR | TLSI |
|---|---|---|
| Price | $13.55 | $5.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $40.00 | $7.00 |
| AVG Volume (30 Days) | ★ 677.0K | 204.0K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.88 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $164,872,000.00 | $45,151,000.00 |
| Revenue This Year | $55.02 | $35.45 |
| Revenue Next Year | $65.66 | $37.58 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 51.97 | ★ 53.41 |
| 52 Week Low | $13.18 | $2.20 |
| 52 Week High | $94.06 | $7.95 |
| Indicator | BETR | TLSI |
|---|---|---|
| Relative Strength Index (RSI) | 33.79 | 60.56 |
| Support Level | N/A | $3.77 |
| Resistance Level | $28.72 | $5.58 |
| Average True Range (ATR) | 2.31 | 0.36 |
| MACD | -0.44 | 0.02 |
| Stochastic Oscillator | 1.89 | 59.57 |
Better Home & Finance Holding Co is a technology-enabled homeownership company that provides mortgage, home equity, and related services through a digital platform. The company operates through two reportable segments: Home Finance, which focuses on residential mortgage origination, including purchase, refinance, and home equity products, generating revenue mainly from loan sales; and Banking, which, through its U.K. subsidiary Birmingham Bank, offers a range of financial products and services to consumers and small businesses. It generates the majority of its revenue from the Home Finance segment.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.